Carregant...
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved as a treatment for type 2 diabetes mellitus (T2DM) in the United States, the European Union and other countries. Dapagliflozin increases renal glucose excretion in an insulin-independent manner, and its mechanism...
Guardat en:
| Publicat a: | Ther Adv Endocrinol Metab |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4480550/ https://ncbi.nlm.nih.gov/pubmed/26137213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018815575273 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|